What it is: A small molecule that blocks an enzyme linked to fat cell activity and NAD+ metabolism, included here because it is commonly studied alongside peptide longevity protocols.
Research suggests: Preclinical studies show it may reduce body fat and improve metabolic markers without affecting lean muscle mass.
Best for: Metabolic and longevity researchers
Key thing to know: Not technically a peptide and has no human clinical trial data yet; all meaningful evidence is from preclinical studies.
What is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme expressed mainly in adipose tissue that helps regulate NAD+ metabolism and fat-cell differentiation. It is not technically a peptide, but it's included here because it is commonly researched alongside peptide protocols in longevity and metabolic settings, and its mechanism connects directly to NAD+ biology.
NNMT activity in fat tissue has been linked to obesity, reduced cellular NAD+ availability, and impaired adipocyte metabolism. The rationale for inhibiting NNMT is that it may redirect more nicotinamide toward NAD+ synthesis, improving metabolic function in fat cells. This places 5-Amino-1MQ at the intersection of two active research areas: NAD+ biology and adipose-tissue metabolism.
Research interest grew significantly following publications from University of Texas Southwestern Medical Center showing dramatic reductions in fat mass and metabolic improvements in mouse models fed high-fat diets. As of 2025, no human clinical trial data has been published.
How it works.
In research, the proposed mechanism has several parts.
NNMT and NAD+: NNMT catalyzes the methylation of nicotinamide using SAM (S-adenosylmethionine), converting it into 1-methylnicotinamide and removing it from the pool available for NAD+ synthesis. In fat tissue, high NNMT activity reduces NAD+ precursor availability (impairing mitochondrial function in adipocytes) and shifts methylation balance, since SAM consumption limits other methylation reactions that regulate gene expression.
Inhibiting NNMT: By inhibiting NNMT, 5-Amino-1MQ is proposed to increase the nicotinamide pool available for NAD+ synthesis, restore methylation balance, and improve adipocyte metabolism. In mouse studies, this corresponded to reduced fat-cell size, reduced fat mass even on high-fat diets, and improvements in insulin sensitivity and lipid profiles, with higher measured energy expenditure than controls.
In plain terms: Think of NNMT as a drain that pulls nicotinamide away from NAD+ production specifically in fat tissue. 5-Amino-1MQ closes that drain, allowing more nicotinamide to become NAD+. The connected improvement in fat cell biology is the proposed downstream effect. The mechanistic logic is scientifically sound and connects to well-established NAD+ biology.
The open question: Whether the effect size seen in mice translates to humans at comparable doses remains the central unanswered question.
What the research shows.
The research evidence breaks down as follows.
Preclinical only: The published evidence for 5-Amino-1MQ is entirely preclinical, based on mouse models. Key studies from University of Texas Southwestern, in peer-reviewed journals, showed that oral administration to mice on high-fat diets significantly reduced fat-mass accumulation, improved insulin sensitivity, and increased energy expenditure versus controls. The results were striking, and the proposed mechanism is biologically coherent.
The limitation: The limitation is fundamental: all of this data comes from mice. Metabolic research is full of compounds that produced compelling mouse data and then failed in human trials. Translation is particularly uncertain for compounds acting on adipose-tissue metabolism, since human adipose biology differs from rodent biology in ways that are not fully characterized.
No human data: No Phase 1 safety data, no human pharmacokinetic data, and no clinical efficacy trials have been published as of 2025. This creates a situation where the mechanistic rationale is interesting and the animal data is encouraging, but the entire human profile is unknown. That is the defining characteristic of a preliminary-rated compound in this library.
Biomarkers to review first.
Given 5-Amino-1MQ's proposed effects on fat metabolism and NAD+ biology, the following biomarkers provide the most relevant baseline context for any research consideration. Understanding your metabolic starting point is essential before evaluating whether this compound is appropriate to research.
What it's commonly researched with.
In research and longevity protocol discussions, 5-Amino-1MQ frequently appears alongside compounds that share its metabolic and NAD+ biology focus. The combinations below reflect what researchers discuss in this context, not recommendations for use.